

Technologies Available for LICENSING

OFFICE OF TECHNOLOGY LICENSING

https://licensing.research.gatech.edu | techlicensing@gtrc.gatech.edu

Novel Repressor Proteins for Gene Regulation and CRISPRi

A solution to CRISPRi's limitations

The current gold standard for decreasing gene expression in human cells is to use a dCas9-Zim3KRAB, a dCas9-10 KOX1KRAB, or a dCas9-KOX1KRAB+MeCP2 protein that can be targeted to a gene's promoter and shut down its expression. The current CRISPRi limitations include incomplete gene knockdown, sgRNA sequencedependent repression activity, and variable performance across human cancer cell lines. Therefore, what is needed is new CRISPR interference system that addresses these issues.

A new CRISPRi platform to develop CRISPR-based therapeutic agents

This invention is comprised of methods and compositions of a new Cas CRISPR gene interference (CRISPRi) platform that uses novel fusion proteins to target a gene's promoter for inhibition and/or deletion. The central aim of this technology is to enable the development of CRISPR-based therapeutic agents.

Summary Bullets

- The new CRISPRi platform uses novel fusion proteins to specifically inhibit target genes of interest and overcome the off-target issues with existing CRISPR platforms already on the market.
- The technology can be used as a life science tool and/or for diagnostics and therapeutics.
- The platform aims to limit off-target editing, circumvent incomplete gene knockdown sgRNA sequencedependent repression activity, and variable performance across human cancer cell lines.

Potential Commercial Applications

- A novel CRISPRi platform that uses novel fusion proteins to specifically inhibit target genes of interest.
- Potential to overcome the off-target issues with existing CRISPR platforms already on the market.
- Use as a life science tool and/or for diagnostics and therapeutics.
- Invention aims to limit off-target editing, circumvent incomplete gene knockdown sgRNA sequencedependent repression activity, and variable performance across human cancer cell lines

Inventors

Dr. John Blazeck
Assistant Professor - Georgia Tech School of Chemical and Biomolecular Engineering

IP Status

Patent application has been filed:

Publications

, -

Images

Visit the Technology here:

Novel Repressor Proteins for Gene Regulation and CRISPRi

https://s3.sandbox.research.gatech.edu//print/pdf/node/4242